Stereotactic Body Radiotherapy in Bulky Hepatocellular Carcinoma with or without Portal Vein Thrombosis: A Feasibility Review in an Egyptian Cohort

被引:0
|
作者
Hegazy, Mohamed Wahba [1 ]
Attallah, Hany [2 ]
El-Shahat, Khaled M. [3 ]
Mostafa, Emad [4 ]
Yassin, Adel [3 ]
Haggag, Ibraheem [4 ]
Fathy, Talaat [5 ]
Monem, Sameh M. Abdel [5 ]
Abdelmoaty, Ahmed [5 ]
Bessar, Ahmed A. [6 ]
机构
[1] Med Coll, Dept Clin Oncol & Nucl Med, Zagazig, Egypt
[2] Int Med Ctr IMC, Dept Radiat Oncol, Cairo, Egypt
[3] Al Azhar Coll Med, Dept Clin Oncol, Cairo, Egypt
[4] Int Med Ctr, Med Radiat Phys, Cairo, Egypt
[5] Coll Med, Trop Dept, Zagazig, Egypt
[6] Coll Med, Radiol Dept, Zagazig, Egypt
关键词
Stereotactic; Hepatocellular; Portal; Veins; Thrombosis; RADIATION-THERAPY; LIVER TOXICITY;
D O I
10.30476/mejc.2023.98866.1918
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) complicated by portal vein thrombosis presents significant clinical challenges. This study aims to retrospectively assess the feasibility of stereotactic irradiation for treating bulky HCC, with or without vascular invasion. Method: In this retrospective analysis, the radiotherapy treatment plans and clinical follow-up data of 22 patients diagnosed with HCC, with or without portal vein thrombosis, were reviewed. These patients underwent stereotactic body radiation therapy (SBRT) between September 2019 and September 2022. Treatment involved administering 40-50 Gy in 5 fractions using SBRT with volumetric modulated arc therapy (VMAT)/4D-computed tomography. Descriptive statistics were utilized without the application of statistical tests. Results: The mean age of the patients was 65 years, with 77% being male. Portal vein thrombosis was present in 73% of the cases, and the average tumor size was 7.2 cm (range 5-12 cm). 59% of patients were classified as Child -Pugh B. The median follow-up duration was 8 months (range 3-36 months). At 3 months, tumor response assessments revealed that 59% of patients had a partial response and 41% had stable disease; by 6 months, 37% achieved complete response, 26% maintained a partial response, and 37% had stable condition. Failure patterns included intrahepatic failure in two patients (at 7 and 9 months) and extrahepatic loss in two others (at 6 and 10 months). Radiation -induced liver disease occurred in two patients at 9- and 11 -weeks posttreatment, respectively. Liver cancer -specific mortality was 13.6%, while non -liver cancer -specific mortality stood at 9%. The progression -free survival rate was 82%. Conclusion: SBRT via VMAT represents a highly cost-effective, non-invasive local therapy with a favorable therapeutic ratio for treating bulky HCC cases, with or without vascular invasion.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [31] Diagnosis of portal vein thrombosis in cirrhotic patients with and without hepatocellular carcinoma
    Waleed M. Serag
    Basem E. Eysa
    Egyptian Liver Journal, 12
  • [32] Diagnosis of portal vein thrombosis in cirrhotic patients with and without hepatocellular carcinoma
    Serag, Waleed M.
    Eysa, Basem E.
    EGYPTIAN LIVER JOURNAL, 2022, 12 (01)
  • [33] Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy
    Matsuo, Yoshiro
    Yoshida, Kenji
    Nishimura, Hideki
    Ejima, Yasuo
    Miyawaki, Daisuke
    Uezono, Haruka
    Ishihara, Takeaki
    Mayahara, Hiroshi
    Fukumoto, Takumi
    Ku, Yonson
    Yamaguchi, Masato
    Sugimoto, Koji
    Sasaki, Ryohei
    JOURNAL OF RADIATION RESEARCH, 2016, 57 (05) : 512 - 523
  • [34] Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma
    Kibe, Yuichi
    Takeda, Atsuya
    Tsurugai, Yuichiro
    Eriguchi, Takahisa
    Oku, Yohei
    Kimura, Yuto
    Nakamura, Naoki
    ACTA ONCOLOGICA, 2022, 61 (01) : 104 - 110
  • [35] A comparative study of treatment on portal vein tumor thrombosis in hepatocellular carcinoma with stereotactic radiotherapy versus three-dimensional conformal radiotherapy
    Katano, Atsuto
    Yamashita, Hideomi
    Nakagawa, Keiichi
    INDIAN JOURNAL OF CANCER, 2024, 61 (01) : 11 - 15
  • [36] Role of radiotherapy in treatment of portal vein thrombosis from advanced hepatocellular carcinoma
    Kim, J.
    Lim, Y.
    Lee, H.
    Kim, K.
    Suh, D.
    Won, H.
    Choi, E.
    Ahn, S.
    Yoon, S.
    Kim, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S299 - S299
  • [37] Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma
    Kim, DY
    Park, W
    Lim, DH
    Lee, JH
    Yoo, BC
    Paik, SW
    Kho, KC
    Kim, TH
    Ahn, YC
    Huh, SJ
    CANCER, 2005, 103 (11) : 2419 - 2426
  • [38] Is radiotherapy the best option for treating hepatocellular carcinoma with portal vein tumour thrombosis?
    Yin, Jun
    Lai, Xin
    Zhang, Peng
    Lang, Jin-Yi
    LIVER INTERNATIONAL, 2017, 37 (02) : 307 - 308
  • [39] Dose-response relationship of radiotherapy for portal vein thrombosis of hepatocellular carcinoma
    Lim, D
    Kim, D
    Park, W
    Yoo, B
    Paik, S
    Kho, K
    Choi, M
    Kim, T
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S271 - S271
  • [40] Outcomes with radiotherapy in multimodality treatment for hepatocellular carcinoma with portal vein tumour thrombosis
    Sahai, Puja
    Yadav, Hanuman Prasad
    Choudhury, Ashok
    Shasthry, Saggere Muralikrishna
    Jindal, Ankur
    Mall, Aprajita
    Mukund, Amar
    Patidar, Yashwant
    Bharadwaj, Mangu Srinivas
    Khangembam, Bangkim Chandra
    Kumar, Guresh
    Rastogi, Archana
    Pamecha, Viniyendra
    BJR OPEN, 2025, 7 (01):